Expanded Access Policy

Dispatch Bio is committed to advancing novel immunotherapies for patients with solid tumors. Our investigational therapies are currently in early-stage clinical and preclinical development, and clinical trials are the primary pathway for patients to access these investigational treatments.

At this time, Dispatch does not offer expanded access (also known as “compassionate use” or “pre-approval access”) to its investigational products. Sufficient safety and efficacy data to support use outside of a controlled clinical trial are not yet available, and our current clinical supply is reserved for our ongoing and planned trials.

Patients and physicians interested in Dispatch’s clinical programs are encouraged to visit ClinicalTrials.gov for information on study eligibility, locations, and enrollment.

This policy will be reviewed periodically and updated as our programs progress. Posting of this policy does not guarantee access to any investigational drug.

 

Last updated: May 2026